Arbele, a Hong Kong-based biotechnology company focused on developing innovative targeted cancer therapies, announced on Wednesday that it has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for ARB1002, its investigational antibody-drug conjugate (ADC) for the treatment of pancreatic cancer.
ARB1002 is composed of an anti-CDH17 monoclonal antibody chemically linked to a potent cytotoxic agent. The ADC is designed to selectively bind CDH17, a cell-surface adhesion molecule overexpressed in pancreatic cancer, enabling targeted delivery of the cytotoxic payload to tumour cells while limiting off-target exposure.
ARB1002 is planned to enter a Phase 1 clinical trial this year, with Arbele completing IND-enabling studies to support its clinical assessment in pancreatic cancer.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Formation Bio acquires worldwide rights to FHND5032 from CTFH
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
Almirall receives China approval for Seysara to treat moderate-to-severe acne